Loading
Before a trial is finalised, run its entry rules against records of real patients with that cancer and report what fraction would qualify. If it is under half, explain why.
An 'eligibility impact statement' in the protocol: the criteria are applied to a de-identified real-world cohort (EHR-derived or registry) and the eligible fraction, its demographic profile and the criteria excluding the most patients are reported. Work using real-world oncology data has shown that relaxing common criteria roughly doubles the eligible population with little change in estimated treatment effect.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Real-world evidence, Weak real-world evidence and registries.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Real-world evidence, Weak real-world evidence and registries, Trials enrol too few, too slowly.
Shares AI trial matching & clinical decision support, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Trials enrol too few, too slowly.
Shares AI trial matching & clinical decision support, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly.